Skip to main content
. Author manuscript; available in PMC: 2022 Oct 8.
Published in final edited form as: Br J Haematol. 2022 May 4;198(2):307–316. doi: 10.1111/bjh.18214

Table 2.

Patient characteristics of the non-deceased iMCD and deceased iMCD cohorts.

Characteristic Deceased iMCD group
(n = 6)		 Non-deceased iMCD group
(n = 66)
Age at diagnosis, years: median (range) 52·4 (15·2–66·7) 37·3 (2·6–71·3)
Male, % 50·0 53·0
TAFRO cases, % 83·3 51·5
Histopathology, %
   Hypervascular 66·7 59·1
   Plasmacytic 0·0 7·6
   Mixed 16·7 28·8
   Not stated 16·7 4·5
Nationality, %
   American 66·7 89·4
   Other 33·3 10·6

iMCD, idiopathic multicentric Castleman disease; TAFRO, thrombocytopenia, anasarca, fever, reticulin myelofibrosis, renal dysfunction and organomegaly.